Do placebos harm patients in IBD trials?

Affiliations

¹ IBD Unit, Hospital Clínico Universitario Lozano Blesa, Facultad de Medicina de Zaragoza, IIS Aragón, CIBEREHD, Zaragoza 50009, Spain. Electronic address: fgomollo@unizar.es.

Comment

Fernando Gomollón. Lancet Gastroenterol Hepatol. 2024 Nov.

. 2024 Nov;9(11):970-972.

doi: 10.1016/S2468-1253(24)00269-3. Epub 2024 Sep 20.

¹ IBD Unit, Hospital Clínico Universitario Lozano Blesa, Facultad de Medicina de Zaragoza, IIS Aragón, CIBEREHD, Zaragoza 50009, Spain. Electronic address: fgomollo@unizar.es.

No abstract available

Comment on

Cortisone in ulcerative colitis; final report on a therapeutic trial.
TRUELOVE SC, WITTS LJ. TRUELOVE SC, et al. Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041. Br Med J. 1955. PMID: 13260656 Free PMC article. No abstract available.
Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Din S, Segal J, Blackwell J, Gros B, Black CJ, Ford AC. Din S, et al. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):1020-1029. doi: 10.1016/S2468-1253(24)00264-4. Epub 2024 Sep 20. Lancet Gastroenterol Hepatol. 2024. PMID: 39307145
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis.
Gros B, Blackwell J, Segal J, Black CJ, Ford AC, Din S. Gros B, et al. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):1030-1040. doi: 10.1016/S2468-1253(24)00233-4. Epub 2024 Sep 20. Lancet Gastroenterol Hepatol. 2024. PMID: 39307146